Bristol Myers Squibb (NYSE:BMY) has tapped Cristian Massacesi, as executive vice president, chief medical officer, and head of development, effective August 1, 2025. Massacesi most recently served as ...

AstraZeneca’s top medical executive Cristian Massacesi will replace Bristol Myers’ current chief medical officer, Samit ...

Cristian Massacesi, M.D., Joins Bristol Myers Squibb as Executive Vice President, Chief Medical Officer and Head of Development ...

Detailed price information for Bristol-Myers Squibb Company (BMY-N) from The Globe and Mail including charting and trades.

Bristol Myers Squibb said on Friday its blockbuster drug Reblozyl in combination with another therapy failed to meet the main ...

Bristol Myers Squibb is undervalued despite challenges. Learn how BMY stock's strong pipeline, cash flow, and growth strategies offset patent expiries.

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same ...

To get a sense of who is truly in control of Bristol-Myers Squibb Company (NYSE:BMY), it is important to understand the ...

Bristol Myers Squibb has appointed Cristian Massacesi, M.D., as Executive Vice President, Chief Medical Officer, and Head of Development.

The program is the latest example of pharmaceutical companies bypassing traditional drug distribution channels for people who ...

BofA cuts Bristol Myers' 2025 EPS and sales estimates slightly and flags medium-term pressure from generics, while ...

The Subject Expert Committee (SEC) under the Cardiovascular division of the Central Drugs Standard Control Organisation ...